Analysis of Nanoparticle-Adjuvant Properties In Vivo
Nanoparticles can be engineered for targeted antigen delivery to the immune cells and for stimulating the immune response to improve the antigen immunogenicity. This approach is commonly used to develop nanotechnology-based vaccines. In addition, some nanotechnology platforms may be initially designed for drug delivery, but in the course of subsequent characterization, their additional immunomodulatory functions may be discovered that can potentially benefit vaccine efficacy. In both of these scenarios, an in vivo proof of concept study to verify the utility of the nanocarrier for improving vaccine efficacy is needed. Here, we describe an experimental approach and considerations for designing an animal study to test adjuvant properties of engineered nanomaterials in vivo.
Key wordsNanoparticles Vaccines Adjuvant Antigen Antibody
This project has been funded in whole or in part by federal funds from the National Cancer Institute, National Institutes of Health, under contract HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.
- 5.Walsh MC, Banas JA, Mudzinski SP, Preissler MT, Graziano RF, Gosselin EJ (2003) A two-component modular approach for enhancing T-cell activation utilizing a unique anti-FcgammaRI-streptavidin construct and microspheres coated with biotinylated-antigen. Biomol Eng 20(1):21–33CrossRefPubMedGoogle Scholar
- 8.Mottram P, Leong D, Crimeen-Irwin B, Gloster S, Xiang SD, Meanger J, Ghildyal R, Vardaxis N, Plebanski M (2007) Type 1 and type 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus. Mol Pharm 4(1):73–84. doi: 10.1021/mp060096p CrossRefPubMedGoogle Scholar
- 10.Weiss R, Scheiblhofer S, Freund J, Ferreira F, Livey I, Thalhamer J (2002) Gene gun bombardment with gold particles displays a particular Th2-promoting signal that over-rules the Th1-inducing effect of immunostimulatory CpG motifs in DNA vaccines. Vaccine 20(25–26):3148–3154. doi: 10.1016/s0264-410x(02)00250-5 CrossRefPubMedGoogle Scholar
- 20.Villanueva A, Cañete M, Roca AG, Calero M, Veintemillas-Verdaguer S, Serna CJ, Morales Mdel P, Miranda R (2009) The influence of surface functionalization on the enhanced internalization of magnetic nanoparticles in cancer cells. Nanotechnology 20(11):115103. doi: 10.1088/0957-4484/20/11/115103 CrossRefPubMedGoogle Scholar
- 23.Thiele L, Rothen-Rutishauser B, Jilek S, Wunderli-Allenspach H, Merkle HP, Walter E (2001) Evaluation of particle uptake in human blood monocyte-derived cells in vitro. Does phagocytosis activity of dendritic cells measure up with macrophages? J Control Release 76(1-2):59–71CrossRefPubMedGoogle Scholar
- 27.Fesenkova V (2013) Nanoparticles and dendritic cells. In: Dobrovolskaia MA, McNeil SE (eds) Handbook of immunological properties of engineered nanomaterials. World Scientific Publishing Ltd., SingaporeGoogle Scholar
- 28.Xiang SD, Fuchsberger M, JKarlson TDL, Hardy CL, Selomulya C, Plebanski M (2013) Nanoparticles, immunomodulation and vaccine delivery. In: Dobrovolskaia MA, McNeil SE (eds) Handbook of immunological properties of engineered nanomaterials. World Scientific Publishing Ltd., SingaporeGoogle Scholar